In the third quarter, GDS Wealth Management reduced its holdings in UnitedHealth Group by 10.7%, selling 5,297 shares and retaining 44,252 shares at quarter end. The divestiture brought the firm’s position to approximately $15.28 million in market value, underscoring a tactical portfolio shift away from the healthcare conglomerate despite its consistent operational growth and diversified revenue streams.

Several smaller funds initiated or increased positions during the same period. LFA Lugano Financial Advisors opened a new stake worth about $25,000, Sagard Holdings deployed $29,000, Grey Fox Wealth Advisors committed $33,000, and Islay Capital Management invested roughly $31,000. Conversely, Riggs Asset Management boosted its holding by 69.4%, adding 43 shares to reach 105 shares valued at $33,000. These moves reflect selective confidence in UnitedHealth’s long-term prospects despite wide-ranging market volatility.

Jefferies lifted its price objective to $409 and reaffirmed a buy recommendation after the insurer reported better-than-expected quarterly earnings per share. Goldman Sachs initiated coverage with a buy rating and a $406 target. UBS increased its forecast to $430, while Piper Sandler maintained an overweight stance with a slightly lower target of $417. Collectively, one Strong Buy, seventeen Buy, nine Hold and two Sell ratings yield a consensus Moderate Buy sentiment, supported by robust revenue growth and margin stability projections.

Institutional investors control 87.9% of UnitedHealth’s shares, signaling deep commitment from large asset managers. The company recently declared a quarterly dividend representing an $8.84 annualized payout and a yield near 2.5%. With a payout ratio below 50% and free cash flow normalization underway, the dividend appears well-supported. This stable income component, combined with diversified business platforms, reinforces UnitedHealth’s appeal to income-oriented investors.